目的 使用網(wǎng)絡(luò)藥理學(xué)方法探討黃芪治療代謝相關(guān)脂肪性肝?。∕AFLD）的作用機(jī)制。方法 根據(jù)TCMSP數(shù)據(jù)庫、GeneCards數(shù)據(jù)庫和比較毒物基因組學(xué)數(shù)據(jù)庫數(shù)據(jù)庫，預(yù)測和篩選黃芪的活性成分和MAFLD的相關(guān)基因，得到黃芪治療MAFLD的潛在靶點(diǎn)，使用Cytoscape 3.8.0軟件和STRING數(shù)據(jù)庫，構(gòu)建黃芪活性成分與MAFLD相關(guān)靶點(diǎn)的成分-靶點(diǎn)網(wǎng)絡(luò)，分析網(wǎng)絡(luò)獲得重要靶點(diǎn)，并利用Metascape數(shù)據(jù)庫對其進(jìn)行GO和KEGG通路富集分析。結(jié)果 從黃芪中篩選得到葉酸、槲皮素、山柰酚、異鼠李素等20個活性成分，能夠作用于91個MAFLD相關(guān)靶點(diǎn)，其中IL4、EGFR、MAPK8、TNF、HIF-1α等27個靶點(diǎn)是重要靶點(diǎn)，可能通過調(diào)控糖尿病并發(fā)癥AGE-RAGE信號通路、白細(xì)胞介素-17信號通路、流體剪切應(yīng)力與動脈粥樣硬化等通路，參與調(diào)節(jié)MAFLD脂質(zhì)代謝、氧化應(yīng)激反應(yīng)和炎癥反應(yīng)等多種生物過程。結(jié)論 黃芪可以通過多靶點(diǎn)、多途徑參與MAFLD的治療。

Objective To investigate the mechanism of Astragali Radix in treatment of metabolic associated fatty liver disease (MAFLD) by means of network pharmacology. Methods According to TCMSP database, GeneCards database, and Comparative Toxicogenomics database, predict and screen the active ingredients of Astragali Radix and related genes of MAFLD, obtain the potential targets of Astragali Radix for treating MAFLD. Cytoscape 3.8.0 software and STRING database was used to construct a component-target network between active ingredients and potential targets. Analyze the network to obtain important targets, and use Metascape database to annotate important targets with gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Results Astragali Radix contains 20 active components such as quercetin, kaempferol, isorhamnetin and folic acid, which can act on 91 MAFLD targets. Among them, 27 targets are key targets, such as IL4, EGFR, MAPK8, TNF and HIF-1α, which can regulate AGE-RAGE signaling pathway in diabetic complications, IL-17 signaling pathway, fluid shear stress and atherosclerosis, involved lipid metabolism, oxidative stress and inflammatory response and other biological processes. Conclusion Astragali Radix play a role in treatment of MAFLD through multiple targets and pathways.

R284.3

國家重點(diǎn)研發(fā)計(jì)劃“中醫(yī)藥現(xiàn)代化研究”專項(xiàng)（2018YFC1705700）；艾滋病和病毒性肝炎等重大傳染病防治專項(xiàng)（2018ZX10303-502）；京津冀中醫(yī)國家臨床重點(diǎn)?？聘尾f(xié)同病房項(xiàng)目（GZY-GCS-2017-60）；中國科學(xué)技術(shù)協(xié)會“青年人才托舉工程（No.2016QNRC001）